LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results
European Journal of Arrhythmia & Electrophysiology · 2016
DOI: 10.17925/ejae.2016.02.01.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Arrhythmia & Electrophysiology, 2016. Verfasst von José Silva Cardoso. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
This editorial summarises important findings from the PARADIGM-HF study. PARADIGM-HF indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.
Zitieren
APA
Cardoso, J. S. (2016). LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results. European Journal of Arrhythmia & Electrophysiology. https://doi.org/10.17925/ejae.2016.02.01.14
Vancouver
Cardoso JS. LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results. European Journal of Arrhythmia & Electrophysiology. 2016. doi:10.17925/ejae.2016.02.01.14
BibTeX
@article{Cardoso2016,
author = {Cardoso, José Silva},
title = {LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results},
journal = {European Journal of Arrhythmia & Electrophysiology},
year = {2016},
doi = {10.17925/ejae.2016.02.01.14}
}
EUVIMED